Prevenar 13 licensed from 5 years

The conjugate pneumococcal vaccine Prevenar 13 is now licensed for use in children aged 5-17 years.

Prevenar 13 was recently approved for the prevention of invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and over.
Prevenar 13 was recently approved for the prevention of invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and over.

Prevenar 13 is indicated for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae. The dose in children aged 5–17 years is 0.5ml by intramuscular injection, preferably into the deltoid muscle of the upper arm.

In an open-label study (n=592), a single dose of Prevenar 13 was given to children aged 5–10  years who had received at least one previous dose of Prevenar (7-valent) and to children aged 10–17 years who had never received a pneumococcal vaccine.

IgG response non-inferior to four-dose course in younger children

In all patients, the immune response to all 13 serotypes, as measured by serum IgG, was non-inferior to that observed in infants who received a four-dose course of Prevenar 13. In addition, functional antibody geometric mean titres one month following vaccination in children aged 10–17 years were non-inferior to those observed in the 5–10 year age group for 12 of the 13 serotypes (except serotype 3).

View Prevenar 13 drug record


Further information: Pfizer Ltd

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.